Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 3Recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 18Neoplasm Metastasis 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Endometrial Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Adenocarcinoma 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Vulvar Neoplasms 1Vomiting 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cystic Neoplasm 1Pancreatic Adenocarcinoma Metastatic 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × Taxes × Clear all
NCT06385925 2026-04-24

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2 Recruiting
440 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07259590 2025-12-02

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2 Recruiting
126 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡